Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18426324 | PE-STOP Gene Editing System and Gene Knockout Method and Application | January 2024 | April 2025 | Abandon | 15 | 2 | 1 | Yes | No |
| 18529537 | MYCOVIRUS-INDUCED GENE SILENCING VECTOR, CONSTRUCTION METHOD AND APPLICATION THEREOF | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18500831 | COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY | November 2023 | November 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18493604 | BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT | October 2023 | August 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18478808 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | September 2023 | February 2026 | Allow | 28 | 0 | 0 | No | No |
| 18342331 | COMBINATION THERAPIES FOR TREATING CANCER | June 2023 | September 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18332076 | HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF | June 2023 | January 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18141363 | METHODS OF MODIFYING A TARGET POLYNUCLEOTIDE UTILIZING TYPE V CRISPR NUCLEASE POLYPEPTIDES FUSED TO MULTIPLE NUCLEAR LOCALIZATION SIGNALS | April 2023 | November 2025 | Abandon | 31 | 4 | 1 | No | No |
| 18306562 | A BISPECIFIC ANTAGONIST COMPRISING A LAG-3 BINDING DOMAIN | April 2023 | June 2025 | Allow | 25 | 1 | 0 | No | No |
| 18137113 | DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS | April 2023 | August 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18300825 | TREATMENT OF METASTATIC BREAST CANCER | April 2023 | May 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18188098 | Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof | March 2023 | July 2025 | Allow | 28 | 1 | 0 | No | No |
| 18183467 | TREATMENT WITH ANTI-VEGF ANTIBODIES | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18183107 | TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF | March 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18179289 | METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC) | March 2023 | July 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18169205 | ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | February 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18161656 | ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSION | January 2023 | June 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18161163 | SINGLE DOMAIN ANTIBODIES TARGETING CD1D | January 2023 | June 2024 | Allow | 16 | 0 | 0 | No | No |
| 18018241 | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | January 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18154380 | COMBINATION THERAPIES COMPRISING AN AGENT THAT BLOCKS THE INTERACTION BETWEEN CD47 AND SIRPa FOR TREATING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER | January 2023 | October 2025 | Allow | 33 | 2 | 0 | No | No |
| 18149972 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER | January 2023 | December 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18003996 | ANTI-B7H3 ANTIBODY AND USE THEREOF | December 2022 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18067669 | ANTI-CTLA4 AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | December 2022 | July 2025 | Allow | 31 | 2 | 0 | No | No |
| 18064070 | CELL SECRETED MINIBODIES AND USES THEREOF | December 2022 | February 2026 | Allow | 38 | 2 | 1 | No | No |
| 18058194 | WNT SIGNALING AGONIST MOLECULES | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 18057949 | KERATINS AS BIOMARKERS FOR CERVICAL CANCER AND SURVIVAL | November 2022 | January 2026 | Abandon | 38 | 3 | 1 | No | No |
| 18057165 | CARRIER-PD-L1 BINDING AGENT COMPOSITIONS FOR TREATING CANCERS | November 2022 | August 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17924371 | VACCINE AGAINST SARS-COV VIRUS | November 2022 | February 2026 | Abandon | 39 | 0 | 0 | No | No |
| 18053878 | CHECKPOINT REGULATOR ANTAGONISTS | November 2022 | April 2025 | Allow | 29 | 1 | 0 | No | No |
| 17998240 | METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18051551 | KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERS | November 2022 | December 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17975887 | CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY | October 2022 | September 2025 | Abandon | 35 | 1 | 1 | No | No |
| 18049793 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | October 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17996209 | ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAME | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17938492 | ANTIGEN BINDING PROTEINS, COMPOSITIONS, AND METHODS OF USING THEREOF | October 2022 | December 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17938270 | AGGF1 IMMUNOGENIC COMPOSITIONS | October 2022 | May 2025 | Allow | 31 | 3 | 0 | No | No |
| 17934232 | PSMA Binding Antibody and Uses Thereof | September 2022 | April 2025 | Allow | 31 | 2 | 0 | No | No |
| 17905662 | RT-PCR DETECTION METHOD AND KIT FOR NOVEL CORONAVIRUS | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17901391 | haNK Cetuximab Combinations And Methods | September 2022 | November 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17802124 | TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY | August 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17886494 | Combination Treatment Method with E10A and PD1 Monoclonal Antibody for Tumor and Pharmaceutical Application | August 2022 | March 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17798261 | ANTIBODIES PROTECTIVE AGAINST INFLUENZA B | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17880558 | Nant Cancer Vaccine | August 2022 | February 2026 | Allow | 42 | 1 | 1 | No | No |
| 17876164 | RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS | July 2022 | November 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17870726 | METHODS OF TREATING PD-L1 EXPRESSING CANCER | July 2022 | May 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17812933 | METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIES | July 2022 | June 2025 | Allow | 35 | 3 | 0 | No | No |
| 17864335 | ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17858710 | NUCLEOLIN-MEDIATED CANCER DIAGNOSTICS AND THERAPY | July 2022 | November 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17855437 | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients | June 2022 | December 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17851462 | METHODS OF DIAGNOSIS AND THERAPEUTIC TARGETING OF CLINICALLY INTRACTABLE MALIGNANT TUMORS | June 2022 | September 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17809098 | PERTUZUMAB VARIANTS AND EVALUATION THEREOF | June 2022 | October 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17847927 | TRANSFORMING GROWTH FACTOR-BETA LIGAND TRAPS FOR THE TREATMENT OF DISEASE | June 2022 | December 2025 | Abandon | 42 | 4 | 1 | No | No |
| 17785590 | METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17807065 | FIXED DOSING OF HER ANTIBODIES | June 2022 | September 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17784617 | BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-Beta | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17835418 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | June 2022 | May 2024 | Allow | 23 | 1 | 0 | No | No |
| 17833383 | BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE | June 2022 | June 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17782415 | BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENT | June 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17781902 | METHODS OF IDENTIFYING AGENTS THAT BLOCK MCD28 CLEAVAGE BY MMPS | June 2022 | December 2025 | Allow | 43 | 1 | 1 | No | No |
| 17826258 | NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA | May 2022 | September 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17777914 | HUMANIZED 4-1BB MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17744271 | IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY | May 2022 | March 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17743350 | COMBINATION THERAPIES FOR TREATING CANCER | May 2022 | June 2024 | Allow | 25 | 1 | 1 | No | No |
| 17776006 | METHODS FOR TREATING CANCER WITH AN ANTI-APO B100 ANTIBODY | May 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17772980 | HUMANIZED ANTI-CA IX ANTIBODIES AND METHODS OF THEIR USE | April 2022 | December 2025 | Allow | 43 | 2 | 0 | No | No |
| 17729970 | NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF | April 2022 | August 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17728491 | BISPECIFIC ANTIGEN BINDING CONSTRUCTS TARGETING HER2 | April 2022 | September 2024 | Allow | 29 | 1 | 0 | No | No |
| 17769881 | USE OF SUCCINATE AS BIOMARKER IN DIAGNOSIS AND TREATMENT OF CANCERS | April 2022 | December 2025 | Allow | 44 | 1 | 1 | No | No |
| 17705960 | METHOD OF IMPROVING EFFICACY OF MELANOMA TREATMENT | March 2022 | November 2025 | Abandon | 44 | 3 | 1 | No | No |
| 17761012 | NKG2D FUSION PROTEINS AND USES THEREOF | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17642868 | TUMOR-TARGETING A56 PROTEIN OR FRAGMENT THEREOF, ANTIBODY BINDING TO A56 PROTEIN, AND USE THEREOF | March 2022 | December 2025 | Allow | 45 | 1 | 1 | No | No |
| 17688740 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION | March 2022 | January 2023 | Allow | 10 | 2 | 0 | No | No |
| 17687169 | In Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method | March 2022 | October 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17652466 | DCIS RECURRENCE AND INVASIVE BREAST CANCER | February 2022 | December 2024 | Allow | 34 | 1 | 1 | No | No |
| 17670146 | THERAPEUTIC COMPOSITION AND METHOD COMBINING MULTIPLEX IMMUNOTHERAPY WITH CANCER VACCINE FOR THE TREATMENT OF CANCER | February 2022 | December 2024 | Allow | 34 | 5 | 1 | No | No |
| 17669177 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS | February 2022 | July 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17592911 | METHODS OF AND COMPOSITIONS FOR REDUCING GENE EXPRESSION AND/OR ACTIVITY | February 2022 | August 2024 | Allow | 30 | 2 | 1 | No | No |
| 17587708 | USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODY | January 2022 | January 2025 | Allow | 36 | 2 | 0 | No | No |
| 17578523 | DETECTION METHOD FOR CANCER USING RNA BIOMARKERS | January 2022 | August 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17575568 | Cytotoxic Particles for Targeting P2X7 Receptor | January 2022 | June 2024 | Allow | 29 | 2 | 0 | No | No |
| 17568376 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | January 2022 | October 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17562727 | METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY | December 2021 | July 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17558906 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma | December 2021 | April 2025 | Allow | 39 | 2 | 1 | No | No |
| 17557801 | CARRIER-BINDING AGENT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | December 2021 | August 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17620381 | ANTI-PROTEASE NEXIN-1 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF TO CONTROL BLEEDING | December 2021 | March 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17550621 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION | December 2021 | June 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17618642 | ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | December 2021 | May 2025 | Allow | 41 | 0 | 1 | No | No |
| 17549367 | Immune Tolerant Elastin-Like Peptide Tetramer Guided Nanoparticles And Methods Of Use | December 2021 | September 2024 | Allow | 33 | 2 | 1 | No | No |
| 17618349 | MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17547748 | MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED O2 DELIVERY | December 2021 | December 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17534774 | THERAPEUTIC SIRP-ALPHA ANTIBODIES | November 2021 | October 2023 | Abandon | 23 | 0 | 0 | No | No |
| 17535313 | TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULES | November 2021 | March 2026 | Abandon | 52 | 4 | 0 | Yes | No |
| 17531753 | TREATING CANCER WITH SIGNAL PEPTIDE-REACTIVE T CELLS | November 2021 | July 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17455651 | Immunocompetence Assessment by Adaptive Immune Receptor Diversity and Clonality Characterization | November 2021 | June 2024 | Allow | 30 | 1 | 1 | No | No |
| 17610897 | CANCER TREATMENT | November 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17505364 | GENE THERAPY FOR MESOTHELIOMA | October 2021 | March 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17480721 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION | September 2021 | December 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17477525 | ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES | September 2021 | May 2024 | Allow | 32 | 1 | 0 | No | No |
| 17476650 | Therapeutic Anti-CD9 Antibody | September 2021 | March 2024 | Allow | 30 | 2 | 1 | No | No |
| 17472552 | PROGRAMMED DEATH 1 LIGAND 1 (PD-L1) BINDING PROTEINS AND METHODS OF USE THEREOF | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GODDARD, LAURA B.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 8.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GODDARD, LAURA B works in Art Unit 1642 and has examined 1,553 patent applications in our dataset. With an allowance rate of 45.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner GODDARD, LAURA B's allowance rate of 45.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GODDARD, LAURA B receive 2.03 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GODDARD, LAURA B is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.7% benefit to allowance rate for applications examined by GODDARD, LAURA B. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.1% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 79.4% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 76.6% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.5% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.